Regeneron Pharmaceuticals, Inc. (REGN) Shares Bought by US Bancorp DE

US Bancorp DE increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 20.1% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 5,145 shares of the biopharmaceutical company’s stock after buying an additional 862 shares during the period. US Bancorp DE’s holdings in Regeneron Pharmaceuticals were worth $2,526,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of REGN. Korea Investment CORP boosted its stake in Regeneron Pharmaceuticals by 223.9% in the first quarter. Korea Investment CORP now owns 298 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 206 shares in the last quarter. FNY Managed Accounts LLC bought a new stake in Regeneron Pharmaceuticals during the first quarter worth about $140,000. Alpha Windward LLC boosted its stake in Regeneron Pharmaceuticals by 4.4% in the first quarter. Alpha Windward LLC now owns 383 shares of the biopharmaceutical company’s stock worth $148,000 after buying an additional 16 shares in the last quarter. Wendell David Associates Inc. bought a new stake in Regeneron Pharmaceuticals during the second quarter worth about $204,000. Finally, Welch & Forbes LLC bought a new stake in Regeneron Pharmaceuticals during the first quarter worth about $211,000. Institutional investors own 67.16% of the company’s stock.

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ REGN) traded up 0.85% on Friday, hitting $467.98. 549,722 shares of the stock were exchanged. Regeneron Pharmaceuticals, Inc. has a 52-week low of $325.35 and a 52-week high of $543.55. The company has a market cap of $49.62 billion, a price-to-earnings ratio of 46.95 and a beta of 1.66. The company has a 50 day moving average of $489.51 and a 200 day moving average of $430.92.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.67 by $1.50. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. The firm had revenue of $1.47 billion for the quarter, compared to analysts’ expectations of $1.36 billion. During the same quarter last year, the business earned $2.82 earnings per share. The business’s revenue was up 21.2% on a year-over-year basis. Equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post $14.85 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This piece was first reported by BNB Daily and is the sole property of of BNB Daily. If you are viewing this piece on another site, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this piece can be viewed at https://www.baseball-news-blog.com/2017/08/19/us-bancorp-de-boosts-stake-in-regeneron-pharmaceuticals-inc-regn-updated-updated.html.

A number of analysts have recently issued reports on the stock. BMO Capital Markets raised their target price on shares of Regeneron Pharmaceuticals from $412.00 to $421.00 and gave the stock a “hold” rating in a research note on Monday, May 15th. Canaccord Genuity set a $522.00 target price on shares of Regeneron Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, August 14th. Leerink Swann reiterated an “outperform” rating and issued a $580.00 price objective (up previously from $573.00) on shares of Regeneron Pharmaceuticals in a research note on Wednesday, August 9th. Vetr cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $408.86 price objective for the company. in a research note on Monday, April 24th. Finally, UBS AG set a $489.00 price objective on shares of Regeneron Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, May 5th. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $495.59.

In other news, Director Joseph L. Goldstein sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, June 9th. The shares were sold at an average price of $482.55, for a total value of $482,550.00. Following the transaction, the director now owns 14,000 shares in the company, valued at $6,755,700. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Chairman P Roy Vagelos sold 9,295 shares of the firm’s stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $458.14, for a total transaction of $4,258,411.30. Following the completion of the transaction, the chairman now owns 414,156 shares in the company, valued at approximately $189,741,429.84. The disclosure for this sale can be found here. Insiders sold 84,404 shares of company stock worth $40,303,792 in the last 90 days. Company insiders own 10.40% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply